Chikungunya Market Trends Support A 9.1% CAGR Outlook Through The Forecast Period

The chikungunya market is on a promising growth path, driven by increasing healthcare investments and advancements in disease prevention and treatment. As efforts to control mosquito-borne illnesses intensify worldwide, this sector is set to witness significant expansion, supported by evolving vaccine developments and diagnostic innovations.

Market Value Projections for the Chikungunya Industry
The chikungunya market is projected to reach a valuation of $1 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.1%. This upward trajectory is fueled by rising investments in vaccine research, heightened emphasis on preventive healthcare measures, and the broadening scope of vector control programs. Additionally, the demand for rapid diagnostic tools and increased global funding aimed at combating emerging diseases contribute significantly to this expansion. Key trends expected to influence the market during this period include the advancement of chikungunya vaccines, wider adoption of antiviral therapies, stronger focus on early disease detection, broader availability of supportive care options, and improved monitoring of mosquito-borne infections.

The chikungunya market size has grown strongly in recent years. It will grow from $0.65 billion in 2025 to $0.71 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to increasing incidence of mosquito-borne viral infections, expansion of endemic regions due to climate variability, limited availability of approved vaccines, reliance on symptomatic treatment approaches, public health monitoring initiatives.

Download a free sample of the chikungunya market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21137&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Players Shaping the Chikungunya Market Landscape
The chikungunya industry features several prominent companies actively driving innovation and market growth. These include F Hoffmann-La Roche Ltd, Merck & Co Inc, Takeda Pharmaceutical Company Limited, Evotec SE, Valneva SE, Vaxart Inc, Inovio Pharmaceuticals Inc, Bharat Biotech International Limited, Moderna Inc, Emergent BioSolutions Inc, GlaxoSmithKline plc, Sanofi Pasteur, Instituto Butantan, Indian Immunologicals Limited, Zydus Lifesciences, BioNTech SE, Novavax Inc, Bavarian Nordic A S, Auro Vaccines LLC, Najit Technologies Inc, Clayton Biotechnologies Inc, and Medigen Vaccine Biologics Corp.

A notable development took place in February 2023 when Bavarian Nordic A/S, a biotechnology firm based in Denmark, acquired travel vaccines from Emergent BioSolutions Inc. for USD 380 million. This acquisition strengthens Bavarian Nordic's position in the travel vaccine market, as it now includes marketed vaccines such as Vivotif for typhoid fever prevention, Vaxchora for cholera, and a phase 3 chikungunya vaccine candidate. Emergent BioSolutions, headquartered in the US, is known for offering chikungunya vaccines among its life sciences products.

View the full chikungunya market report:
https://www.thebusinessresearchcompany.com/report/chikungunya-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Trends Accelerating Progress in the Chikungunya Sector
Leading firms in the chikungunya space are prioritizing the creation of innovative vaccines aimed at boosting immunity, curbing outbreaks, and addressing the rising health challenges posed by chikungunya virus infections globally. One promising approach involves live attenuated vaccines, which use a weakened form of the virus to safely stimulate the immune system and provide enduring protection.

For instance, in November 2023, France-based biotech company Valneva SE announced that its live attenuated chikungunya vaccine, IXCHIQ, received accelerated approval from the US Food and Drug Administration (FDA). This approval hinged on neutralizing antibody titers against CHIKV, with continued approval dependent on further clinical validation. Valneva also secured a Priority Review Voucher (PRV) from the FDA, which it plans to leverage to fund ongoing research and development. IXCHIQ is administered as a single intramuscular injection containing a weakened virus that may cause symptoms similar to chikungunya infection in some recipients.

Breakdown of Segments in the Chikungunya Market Report
The chikungunya market is categorized into several key segments to provide a detailed view of the industry:
1) Type: Antiviral Drugs, Herbal and Complementary Treatments, Supportive Care, Vaccines
2) Product Form: Liquid Form, Powder, Solid Form
3) Disease Stage: Acute, Chronic, Post-Infection
4) Sales Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Supermarkets
5) End User: Caregivers, Healthcare Professionals, Patients

Further subcategories include:
- Antiviral Drugs: Nucleoside Analogues, Protease Inhibitors
- Herbal and Complementary Treatments: Ayurvedic Remedies, Homeopathic Treatments, Traditional Chinese Medicine
- Supportive Care: Pain Relievers (NSAIDs, Acetaminophen), Fluid Therapy, Physiotherapy
- Vaccines: Live-Attenuated Vaccines, Inactivated Vaccines, mRNA-Based Vaccines

This comprehensive segmentation highlights the diverse approaches and products addressing chikungunya, providing a clearer understanding of the market's structure and potential opportunities.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.